All Patents articles
View all stories with this category.
-
OpinionWhen should employees share profits from inventions?
Glucose monitor inventor wins £2m payout from Unilever after claiming his work provided ’outstanding benefit’
-
News
Patient and research groups condemn draft bill allowing human gene patenting in US
A measure floated by Congress could hinder research and access to gene tests and raise their costs
-
Research
Patent-busting AI tool navigates around protected drug pathways
Organic retrosynthesis software can identify key bonds involved in patented reactions to find alternative pathways
-
Opinion
Pushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
-
Opinion
Has Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
Business
‘No deal’ Brexit guidance fails to reassure UK chemical industry
UK government issues guidance on chemical regulation and patent law if the UK leaves the EU without agreement
-
Sponsored
The dark side of chemical patents
Unloved, ignored and misunderstood but could all that change?
-
Sponsored
A guide to searching and using Markush structures
Chemical patents are often very long and difficult to read. Markush searching can enable you to easily categorise and filter the information you need, giving you the insights that a paper sometimes cannot.
-
-
Business
Pharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
Business
Federal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
Business
US government urged to exercise drug patent rights
Campaign group says withdrawing Biogen’s license to government patents, or re-licensing them to other companies, could lower MS drug prices
-
Business
Allergan sidesteps patent review with tribal deal
Native Americans agree to use sovereign immunity to protect intellectual property from double challenge
-
Business
US court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
Business
Broad Institute backs central Crispr patent licensing platform
Key players submit 22 patents to pool, and urge other holders to create a one-stop shop for licensing deals
-
Business
Lilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
-
Business
Silence Therapeutics and Alnylam in patent dispute
Suit alleges competitors need to license Silence patents relating to their drug cantidates
-
Business
US supreme court limits patent rights
Biotech industry is concerned that ruling will hit small companies
-
News
Legal battles stall US biosimilars
Unclear legislation and lack of regulatory guidance means companies are turning to the courts
-
Opinion
Time to stop using patents to measure innovation in universities
The number of filed patents is a misleading metric for assessing academic research
